Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial.

The primary results report of NCT06588283.

What the trial testedas reported · 2026

Not counted

+21.2percentage points+12.8 to +29.7

As reported

difference 21.2 %, 95% CI 12.8–29.7

the abstract, start to end

… with ixekizumab (risk difference [RD], 21.2%; 95% CI, 12.8%-29.7%; …

← favours treatmentfavours comparator →

could be chance

Body weight & composition

21.212.8–29.7

GIP/GLP-1 & amylin agonistsBody weight & composition

1 / 3

2026

this papercites it